Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
NCT03080935 · Amgen · PHASE3 · terminated · last registry update 2024-05-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Amgen business decision to close study early” | – | Registry record, Amgen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-20Results posted on the registry: Novartis Pharmaceuticals, Inclisiran + Matching Placebo for Inclisiran (NCT05888103)
- 2025-03-17Also stopped (withdrawn): University of Louisville, Statin + Aspirin tablet (NCT06280976)
- 2025-02-07Phase 3 first posted: Novartis Pharmaceuticals, Pelacarsen + Placebo (NCT06813911)
- 2025-01-27Also stopped (terminated): Monash University, a drug against PCSK9 (NCT05834673)
- 2024-11-21Also stopped (withdrawn): Fondazione IRCCS Policlinico San Matteo di Pavia, Evolocumab (NCT04303377)
- 2024-11-20Phase 3 first posted: Xiang Luo, PCSK9 inhibitors combined with atorvastatin/rosuvastatin + Atorvastatin/Rosuvastatin (NCT06696820)
- 2024-10-17Results posted on the registry: NYU Langone Health, Statin + PCSK9 inhibitor (NCT04369664)
- 2024-09-19Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Placebo (NCT06597006)
- 2024-09-19Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Placebo (NCT06597019)
- 2024-09-19Results posted on the registry: Novartis Pharmaceuticals, Inclisiran (NCT04929249)
- 2024-08-23Phase 3 first posted: Hasten Biopharmaceutical Co., Ltd., Lerodalcibep + matching placebo (NCT06568471)
- 2024-08-06Also stopped (terminated): Imperial College London, Evolocumab + Placebo (NCT04073134)
- 2024-07-17Results posted on the registry: Cedars-Sinai Medical Center, Evolocumab + Omnipaque (NCT03689946)
- 2024-07-10Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Inclisiran (NCT06494501)
- 2024-06-03Results posted on the registry: University of Nebraska, Evolocumab (NCT03944577)
- 2024-05-16Also stopped (terminated): University Hospital Tuebingen, Lowering cholesterol concentrations by PCSK-9 inhibitor (NCT04314167)
- 2024-04-22Results posted on the registry: Food and Drug Administration (FDA), Evolocumab + Evolocumab (NCT04189484)
- 2024-03-25Results posted on the registry: Novartis Pharmaceuticals, Inclisiran + Background lipid lowering therapy (NCT04807400)
- 2024-03-06Results posted on the registry: Novartis Pharmaceuticals, Inclisiran Sodium (NCT03814187)
- 2023-10-13Phase 3 first posted: Sejong General Hospital, Repatha® (NCT06081803)
- 2023-10-12Phase 3 first posted: The First Affiliated Hospital with Nanjing Medical University, Alirocumab + Atorvastatin (NCT06080256)
- 2023-06-05Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Matching Placebo for Inclisiran (NCT05888103)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision